Press & events

What's happening?

Stay updated on our latest news and events.

Displaying 41 - 50 of 92

Insights

In early drug development, the toxicology, bioavailability, pharmacokinetics (PK) and pharmacology of a compound need to be analysed using a liquid formulation. Often solubility becomes a challenge, meaning excipients are needed to optimise the solubility.

Insights

The US Food and Drug Administration (FDA) released the Standardisation of Data and Documentation Practices for Product Tracing guidance last week, which extends the standards outlined in the Drug Supply Chain Security Act (DSCSA).

Insights

The European Medicines Verification Organisation (EMVO) recently published an announcement to confirm that only marketing authorisation holders (MAHs) or parallel distributors (MAH with parallel di

Insights

As we move into 2018 there are a number of trends we can expect to drive activity in the pharmaceutical industry over the coming months.

Insights

Friday 9th February marks one year until the EU Falsified Medicines Directive (FMD) enforcement date. Although a year may sound like a long time it’s a very short period to implement a lot of changes.

Insights

Over the last decade the pharmaceutical industry has experienced unprecedented growth and is estimated to reach $1.5trillion by 2021. This has been driven by an increasing number of breakthrough therapies, expensive treatments for unmet medical needs and an ageing population.

Insights

Fredrik Lehmann PhD, General Manager and Sales Director Preclinical and Chemistry Services at Recipharm, partners with Uppsala Bio to discuss the global services in pharmaceutical development provided by Recipharm’s development facility in Uppsala.

Insights

As we move into 2018, compliance with serialisation regulations is becoming more and more urgent. Implementing suitable solutions puts pressure on contract manufacturing organisations’ (CMOs) internal infrastructure as they find a way to introduce and integrate serialisation with their current systems and improve supply chain communication.

Insights

According to PwC, the counterfeit drug market is worth over $200 billion per annum. In recent months the pharmaceutical industry has taken huge steps to tackle the rising problem of falsified medicines with the introduction of serialisation regulations in more than 50 countries worldwide.

Insights

2017 has been an eventful year in the world of pharma, with new track and trace regulations driving investment and opening up new possibilities in the pharmaceutical supply chain, while consolidation continues to shape the outsourcing sector.